Ligand Pharma (LGND) Tops Q1 EPS by 36c, provides guidance

Ligand Pharma (NASDAQ: LGND) reported Q1 EPS of $1.20, $0.36 better than the analyst estimate of $0.84. Revenue for the quarter came in at $30.98 million versus the consensus estimate of $26.69 million.

GUIDANCE:

Ligand Pharma sees FY2024 EPS of $4.25-$4.75, versus the consensus of $4.44. Ligand Pharma sees FY2024 revenue of $130-142 million, versus the consensus of $137.3 million.

For earnings history and earnings-related data on Ligand Pharma (LGND) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• Ligand Pharma (LGND) Reiterated at Buy by Stifel After Chat With CEO, CFO
• INVO Fertility (IVF) Tops Q2 EPS by 105c